Tuberculosis (TB) surveillance is a vital step toward eradicating a disease that is the second leading infectious disease killer worldwide, behind COVID-19.1 Caused by bacteria in the Mycobacterium tuberculosis complex (MTBC), which includes Mycobacterium tuberculosis (Mtb), TB is a treatable disease but drug-resistant TB (DR-TB) remains a public health crisis and a health security threat.1 Genomic-based TB surveillance can support public health officials in:
The discriminatory power of next-generation sequencing enables outbreaks to be addressed with greater speed and confidence.
NGS is fueling the future of the drug-resistant TB (DR-TB) research landscape. This informative eBook outlines the history and global implications of DR-TB, details examples of how NGS is being used to advance the WHO goal of ending TB, and overviews Illumina workflows that can be applied to TB genomic investigations and research.Download the eBook today
DR-TB is an MTBC that is resistant to one or more anti-TB drugs and represents a significant challenge in controlling the pathogen’s diagnosis, treatment, and eradication.2 Detecting and characterizing these strains are a vital part of disease surveillance.
With its unique ability to broadly capture genetic regions associated with Mtb and anti-TB drug resistance, NGS is well-suited for advancing clinical research on tuberculosis. Insights obtained through NGS include:
Illumina is fully committed to supporting the World Health Organization’s (WHO) mission to end TB. This comprehensive infographic for World TB Day displays information about TB drugs, treatment, surveillance methods, and visualized TB statistics.
On World TB Day in 2023, three accomplished TB researchers discussed how they are using NGS to help accomplish the goal of ending TB.
This kit is a tNGS panel that identifies MTBC strains and mycobacterial species while providing a solution for genotyping and predicting drug resistance mutations for MTBC strains. This is a comprehensive, culture-free solution for characterizing TB drug resistance with fast results in less than 48 hours.Learn More
In this featured article, read how Dr. Camilla Rodrigues is using NGS to fight DR-TB at the P.D. Hinduja Hospital and Medical Research Centre in Mumbai, India.
Read the interview with Dr. Supply, who discusses the growing problem of DR-TB, the values that Illumina next-generation sequencing (NGS) systems bring to their detection, and more.
Read what the scientific lead at South Africa’s Centre for Tuberculosis in Johannesburg believes when it comes to detecting and tracking DR-TB using next-generation sequencing.
Eliminate the need for separate DNA isolation and high-accuracy quantitation steps with the streamlined, cost-effective Flex Direct Colony Method.
In this talk, Dr. Swapna Uplekar, Senior Scientific Officer at FIND, Switzerland, shows how to enable targeted NGS for detection and diagnosis of drug-resistant tuberculosis.